Peyronie’s disease: pharmacological treatments and limitations

Eric V. Li, Robert Esterquest, Minh N. Pham, Evan J. Panken, Channa Amarasekera*, Aisha Siebert, Petar Bajic, Laurence A. Levine

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Introduction: Peyronie’s disease (PD) is a disorder of the tunica albuginea from disordered and excessive deposition of collagen resulting in a palpable scar, pain, erect penile deformity and erectile dysfunction that significantly impacts patients both physically and emotionally. Areas Covered: Several treatment options have been described for PD, including shockwave therapy, traction therapy, both oral and intralesional pharmacological options, and surgery. This review seeks to examine the data for different types of non-surgical treatments for PD. We review how various treatment modalities impact several relevant clinical endpoints for Peyronie’s disease, including effects on pain, penile curvature, plaque formation, and erectile function. We performed a literature search using PubMed and SCOPUS while referencing AUA, EAU, and CUA guidelines for management of Peyronie’s Disease for studies published 1980–2020. Expert opinion: Intralesional collagenase injections have the strongest evidence and are the only FDA approved intralesional treatment for PD. Penile traction therapy (PTT) is low risk and may be beneficial in patients willing to invest significant time using the devices. Furthermore, oral combination therapy with other modalities may provide some benefit. Further investigation is required to better understand pathophysiology of PD and clarify the therapeutic utility of existing treatments, potentially with a multimodal strategy.

Original languageEnglish (US)
Pages (from-to)703-713
Number of pages11
JournalExpert Review of Clinical Pharmacology
Issue number6
StatePublished - 2021
Externally publishedYes


  • intralesional
  • medical management
  • oral
  • Peyronie’s disease
  • topical
  • traction

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Peyronie’s disease: pharmacological treatments and limitations'. Together they form a unique fingerprint.

Cite this